Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

Related Articles by Review for PubMed (Select 22454421)

1.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.

J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.

2.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

Bradley AM, Devine M, DeRemer D.

Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. Review.

PMID:
23515511
3.

Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.

Minich SS.

Ann Pharmacother. 2012 Mar;46(3):377-83. doi: 10.1345/aph.1Q680. Epub 2012 Mar 6. Review.

PMID:
22395252
4.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

Foyil KV, Bartlett NL.

Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15. Review.

PMID:
21463188
5.

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK.

Pharmacotherapy. 2013 Jan;33(1):93-104. doi: 10.1002/phar.1170. Review.

PMID:
23307550
6.

Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?

Goyal SD, Bartlett NL.

Curr Hematol Malig Rep. 2012 Sep;7(3):179-85. doi: 10.1007/s11899-012-0126-1. Review.

PMID:
22669711
7.

Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.

Gualberto A.

Expert Opin Investig Drugs. 2012 Feb;21(2):205-16. doi: 10.1517/13543784.2011.641532. Epub 2011 Nov 30. Review.

PMID:
22127011
8.

[Brentuximab vedotin: new treatment for CD30+ lymphomas].

Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.

Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Review. French.

PMID:
23831822
9.

Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

Haddley K.

Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435. Review.

PMID:
22536568
10.
11.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
12.

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.

Siddiqi T, Thomas SH, Chen R.

Pharmgenomics Pers Med. 2014 Feb 20;7:79-85. doi: 10.2147/PGPM.S57700. eCollection 2014. Review.

13.

Brentuximab vedotin.

van de Donk NW, Dhimolea E.

MAbs. 2012 Jul-Aug;4(4):458-65. doi: 10.4161/mabs.20230. Epub 2012 Jul 1. Review.

14.

Brentuximab vedotin in Hodgkin's lymphoma.

Pro B, Perini GF.

Expert Opin Biol Ther. 2012 Oct;12(10):1415-21. doi: 10.1517/14712598.2012.718328. Epub 2012 Aug 31. Review.

PMID:
22937794
15.

Brentuximab vedotin.

Deng C, Pan B, O'Connor OA.

Clin Cancer Res. 2013 Jan 1;19(1):22-7. doi: 10.1158/1078-0432.CCR-12-0290. Epub 2012 Nov 15. Review.

16.

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

Chen X, Soma LA, Fromm JR.

Onco Targets Ther. 2013 Dec 19;7:45-56. doi: 10.2147/OTT.S39107. Review.

17.

Anti-CD30 Antibodies for Hodgkin lymphoma.

Foyil KV, Bartlett NL.

Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y. Review.

PMID:
20446121
18.

Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.

Younes A.

Hematol Oncol Clin North Am. 2014 Feb;28(1):27-32. doi: 10.1016/j.hoc.2013.10.005. Review.

PMID:
24287065
19.

The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.

Sureda A, Domenech E, Schmitz N, Dreger P; Lymphoma Working Party of the European Group for Stem Cell Transplantation.

Curr Treat Options Oncol. 2014 Jun;15(2):238-47. doi: 10.1007/s11864-014-0287-3. Review.

PMID:
24752768
20.

Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.

Lai CM, Horowitz S.

Expert Rev Hematol. 2013 Aug;6(4):361-73. doi: 10.1586/17474086.2013.814434. Review.

PMID:
23991923
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk